TISIDB

Summary
Symbol	PAX8
Name	paired box 8
Aliases	paired box gene 8; paired domain gene 8; Paired box protein Pax-8
Chromosomal Location	2q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus.
Domain	PF00292 'Paired box' domain PF12403 Paired-box protein 2 C terminal
Function	Transcription factor for the thyroid-specific expression of the genes exclusively expressed in the thyroid cell type, maintaining the functional differentiation of such cells.

> Gene Ontology [ TOP ]
Biological Process	GO:0001655 urogenital system development GO:0001656 metanephros development GO:0001657 ureteric bud development GO:0001658 branching involved in ureteric bud morphogenesis GO:0001763 morphogenesis of a branching structure GO:0001822 kidney development GO:0001823 mesonephros development GO:0001838 embryonic epithelial tube formation GO:0002790 peptide secretion GO:0002791 regulation of peptide secretion GO:0003002 regionalization GO:0003337 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003338 metanephros morphogenesis GO:0003339 regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0006575 cellular modified amino acid metabolic process GO:0006590 thyroid hormone generation GO:0006790 sulfur compound metabolic process GO:0007389 pattern specification process GO:0007423 sensory organ development GO:0009914 hormone transport GO:0010092 specification of animal organ identity GO:0010817 regulation of hormone levels GO:0015833 peptide transport GO:0016331 morphogenesis of embryonic epithelium GO:0018958 phenol-containing compound metabolic process GO:0019827 stem cell population maintenance GO:0023061 signal release GO:0030072 peptide hormone secretion GO:0030856 regulation of epithelial cell differentiation GO:0030858 positive regulation of epithelial cell differentiation GO:0030878 thyroid gland development GO:0032350 regulation of hormone metabolic process GO:0032352 positive regulation of hormone metabolic process GO:0034698 response to gonadotropin GO:0035019 somatic stem cell population maintenance GO:0035148 tube formation GO:0035239 tube morphogenesis GO:0035270 endocrine system development GO:0035850 epithelial cell differentiation involved in kidney development GO:0038194 thyroid-stimulating hormone signaling pathway GO:0039003 pronephric field specification GO:0039017 pattern specification involved in pronephros development GO:0042403 thyroid hormone metabolic process GO:0042445 hormone metabolic process GO:0042471 ear morphogenesis GO:0042472 inner ear morphogenesis GO:0042886 amide transport GO:0043583 ear development GO:0046879 hormone secretion GO:0046883 regulation of hormone secretion GO:0048562 embryonic organ morphogenesis GO:0048568 embryonic organ development GO:0048645 animal organ formation GO:0048732 gland development GO:0048754 branching morphogenesis of an epithelial tube GO:0048793 pronephros development GO:0048839 inner ear development GO:0060231 mesenchymal to epithelial transition GO:0060561 apoptotic process involved in morphogenesis GO:0060562 epithelial tube morphogenesis GO:0060675 ureteric bud morphogenesis GO:0060688 regulation of morphogenesis of a branching structure GO:0060993 kidney morphogenesis GO:0061004 pattern specification involved in kidney development GO:0061005 cell differentiation involved in kidney development GO:0061138 morphogenesis of a branching epithelium GO:0061213 positive regulation of mesonephros development GO:0061217 regulation of mesonephros development GO:0061326 renal tubule development GO:0061333 renal tubule morphogenesis GO:0070460 thyroid-stimulating hormone secretion GO:0071371 cellular response to gonadotropin stimulus GO:0071599 otic vesicle development GO:0072001 renal system development GO:0072003 kidney rudiment formation GO:0072004 kidney field specification GO:0072006 nephron development GO:0072009 nephron epithelium development GO:0072017 distal tubule development GO:0072025 distal convoluted tubule development GO:0072028 nephron morphogenesis GO:0072038 mesenchymal stem cell maintenance involved in nephron morphogenesis GO:0072039 regulation of mesenchymal cell apoptotic process involved in nephron morphogenesis GO:0072040 negative regulation of mesenchymal cell apoptotic process involved in nephron morphogenesis GO:0072044 collecting duct development GO:0072048 renal system pattern specification GO:0072049 comma-shaped body morphogenesis GO:0072050 S-shaped body morphogenesis GO:0072069 DCT cell differentiation GO:0072073 kidney epithelium development GO:0072077 renal vesicle morphogenesis GO:0072078 nephron tubule morphogenesis GO:0072079 nephron tubule formation GO:0072080 nephron tubule development GO:0072087 renal vesicle development GO:0072088 nephron epithelium morphogenesis GO:0072108 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072160 nephron tubule epithelial cell differentiation GO:0072163 mesonephric epithelium development GO:0072164 mesonephric tubule development GO:0072170 metanephric tubule development GO:0072171 mesonephric tubule morphogenesis GO:0072173 metanephric tubule morphogenesis GO:0072174 metanephric tubule formation GO:0072175 epithelial tube formation GO:0072182 regulation of nephron tubule epithelial cell differentiation GO:0072202 cell differentiation involved in metanephros development GO:0072205 metanephric collecting duct development GO:0072207 metanephric epithelium development GO:0072210 metanephric nephron development GO:0072215 regulation of metanephros development GO:0072216 positive regulation of metanephros development GO:0072217 negative regulation of metanephros development GO:0072221 metanephric distal convoluted tubule development GO:0072234 metanephric nephron tubule development GO:0072235 metanephric distal tubule development GO:0072240 metanephric DCT cell differentiation GO:0072243 metanephric nephron epithelium development GO:0072257 metanephric nephron tubule epithelial cell differentiation GO:0072273 metanephric nephron morphogenesis GO:0072278 metanephric comma-shaped body morphogenesis GO:0072282 metanephric nephron tubule morphogenesis GO:0072283 metanephric renal vesicle morphogenesis GO:0072284 metanephric S-shaped body morphogenesis GO:0072289 metanephric nephron tubule formation GO:0072304 regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072307 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072309 mesenchymal stem cell maintenance involved in metanephric nephron morphogenesis GO:0090087 regulation of peptide transport GO:0090183 regulation of kidney development GO:0090184 positive regulation of kidney development GO:0090185 negative regulation of kidney development GO:0090189 regulation of branching involved in ureteric bud morphogenesis GO:0090190 positive regulation of branching involved in ureteric bud morphogenesis GO:0090276 regulation of peptide hormone secretion GO:0090596 sensory organ morphogenesis GO:0097152 mesenchymal cell apoptotic process GO:0098727 maintenance of cell number GO:1900200 mesenchymal cell apoptotic process involved in metanephros development GO:1900204 apoptotic process involved in metanephric collecting duct development GO:1900205 apoptotic process involved in metanephric nephron tubule development GO:1900211 regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900214 regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900217 regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1901145 mesenchymal cell apoptotic process involved in nephron morphogenesis GO:1901147 mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:1901615 organic hydroxy compound metabolic process GO:1902337 regulation of apoptotic process involved in morphogenesis GO:1902338 negative regulation of apoptotic process involved in morphogenesis GO:1902455 negative regulation of stem cell population maintenance GO:1902742 apoptotic process involved in development GO:1904672 regulation of somatic stem cell population maintenance GO:1904673 negative regulation of somatic stem cell population maintenance GO:1904746 negative regulation of apoptotic process involved in development GO:1904748 regulation of apoptotic process involved in development GO:1905330 regulation of morphogenesis of an epithelium GO:1905332 positive regulation of morphogenesis of an epithelium GO:2000027 regulation of organ morphogenesis GO:2000036 regulation of stem cell population maintenance GO:2000592 regulation of metanephric DCT cell differentiation GO:2000594 positive regulation of metanephric DCT cell differentiation GO:2000609 regulation of thyroid hormone generation GO:2000611 positive regulation of thyroid hormone generation GO:2000612 regulation of thyroid-stimulating hormone secretion GO:2000696 regulation of epithelial cell differentiation involved in kidney development GO:2000698 positive regulation of epithelial cell differentiation involved in kidney development GO:2001053 regulation of mesenchymal cell apoptotic process GO:2001054 negative regulation of mesenchymal cell apoptotic process
Molecular Function	GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001046 core promoter sequence-specific DNA binding GO:0001047 core promoter binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001159 core promoter proximal region DNA binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0004996 thyroid-stimulating hormone receptor activity GO:0016500 protein-hormone receptor activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04918 Thyroid hormone synthesis
Reactome	-

Summary
Symbol	PAX8
Name	paired box 8
Aliases	paired box gene 8; paired domain gene 8; Paired box protein Pax-8
Chromosomal Location	2q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PAX8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PAX8
Name	paired box 8
Aliases	paired box gene 8; paired domain gene 8; Paired box protein Pax-8
Chromosomal Location	2q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PAX8 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PAX8
Name	paired box 8
Aliases	paired box gene 8; paired domain gene 8; Paired box protein Pax-8
Chromosomal Location	2q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PAX8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.565	0.113
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.071	0.908
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	1.051	0.0151
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.686	0.264
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.832	0.706
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.5	0.858
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.169	0.752
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.152	0.848
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.272	0.749
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.325	0.871
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.081	0.977
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-1.002	0.0363

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PAX8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PAX8
Name	paired box 8
Aliases	paired box gene 8; paired domain gene 8; Paired box protein Pax-8
Chromosomal Location	2q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PAX8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PAX8
Name	paired box 8
Aliases	paired box gene 8; paired domain gene 8; Paired box protein Pax-8
Chromosomal Location	2q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PAX8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PAX8. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PAX8
Name	paired box 8
Aliases	paired box gene 8; paired domain gene 8; Paired box protein Pax-8
Chromosomal Location	2q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PAX8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PAX8
Name	paired box 8
Aliases	paired box gene 8; paired domain gene 8; Paired box protein Pax-8
Chromosomal Location	2q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PAX8 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PAX8
Name	paired box 8
Aliases	paired box gene 8; paired domain gene 8; Paired box protein Pax-8
Chromosomal Location	2q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PAX8 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PAX8
Name	paired box 8
Aliases	paired box gene 8; paired domain gene 8; Paired box protein Pax-8
Chromosomal Location	2q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PAX8 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PAX8